A citation-based method for searching scientific literature

Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
Times Cited: 253



Sunder Mudaliar, Sindura Alloju, Robert R Henry. Diabetes Care 2016
Times Cited: 302




List of shared articles



Times cited


Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial.
Gian Pio Sorice, Francesca Cinti, Lucia Leccisotti, Domenico D'Amario, Margherita Lorusso, Maria Angela Guzzardi, Teresa Mezza, Camilla Cocchi, Umberto Capece, Pietro Manuel Ferraro,[...]. Diabetes Ther 2021
0


The Evolving Understanding and Approach to Residual Cardiovascular Risk Management.
Devinder S Dhindsa, Pratik B Sandesara, Michael D Shapiro, Nathan D Wong. Front Cardiovasc Med 2020
7

Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial.
Anne Zanchi, Michel Burnier, Marie-Eve Muller, Arlène Ghajarzadeh-Wurzner, Marc Maillard, Nicolas Loncle, Bastien Milani, Nathalie Dufour, Olivier Bonny, Menno Pruijm. J Am Heart Assoc 2020
5

Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13 C magnetic resonance spectroscopy study.
Desiree Abdurrachim, Xing Qi Teo, Chern Chiuh Woo, Wei Xin Chan, Janise Lalic, Carolyn S P Lam, Philip Teck Hock Lee. Diabetes Obes Metab 2019
21

SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
Theodosios D Filippatos, Angelos Liontos, Ioanna Papakitsou, Moses S Elisaf. Postgrad Med 2019
19

Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy.
Riobaldo Cintra, Filipe A Moura, Luis Sergio F de Carvalho, Joaquim Barreto, Marcos Tambascia, Roberto Pecoits-Filho, Andrei C Sposito. Rev Assoc Med Bras (1992) 2019
9

The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Hsiang-Chun Lee, Yi-Lin Shiou, Shih-Jie Jhuo, Chia-Yuan Chang, Po-Len Liu, Wun-Jyun Jhuang, Zen-Kong Dai, Wei-Yu Chen, Yun-Fang Chen, An-Sheng Lee. Cardiovasc Diabetol 2019
32


SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice.
Rebeca Ortega, Aida Collado, Francisca Selles, Herminia Gonzalez-Navarro, Maria-Jesus Sanz, José T Real, Laura Piqueras. Arterioscler Thromb Vasc Biol 2019
14

Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
Devinder S Dhindsa, Anurag Mehta, Pratik B Sandesara, Aneesha Thobani, Stephen Brandt, Laurence S Sperling. Curr Cardiol Rep 2019
2

Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure.
Konstantinos Imprialos, Konstantinos Stavropoulos, Vasilios Papademetriou. Heart Fail Clin 2019
0